Agenus Inc (AGEN) stock
AGENNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$6.21−0.08 (-1.27%)
Close on Nov 17, 2026Market cap $279.58MP/E –Yield –
Agenus price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Agenus's price to sales ratio was 2.3× on Nov 10, 2026, against 1.4× a year earlier. Over the last 5 years it ranged from 0.0× to 171.1×, with a median of 0.8×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 10, 2026 | 2.3× | +1.3 |
| 2025 | Dec 31, 2025 | 1.0× | +0.6 |
| 2024 | Dec 31, 2024 | 0.4× | +0.2 |
| 2023 | Jan 31, 2023 | 0.2× | +0.0 |
| 2022 | Dec 30, 2022 | 0.1× | +0.1 |
| 2021 | Dec 31, 2021 | 0.0× | −171.0 |
| 2018 | Jan 31, 2018 | 171.1× | +16.6 |
| 2017 | Dec 29, 2017 | 154.5× | −134.8 |
| 2016 | Dec 30, 2016 | 289.2× | −61.6 |
| 2015 | Dec 31, 2015 | 350.8× | – |
See a number that looks wrong?